We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Biotech Acquisition Company Warrant in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 48 → 0 (-48)

100% less capital invested

Capital invested by funds: $3.83M → $0 (-$3.83M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 47

Holders
–
Holders Change
-48
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
47
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
RCM
Radcliffe Capital Management
Pennsylvania
-$2.05M
2
BFM
Boothbay Fund Management
New York
-$611K
3
LP
LMR Partners
United Kingdom
-$505K
4
SCM
Segantii Capital Management
Hong Kong
-$252K
5
HIM
HGC Investment Management
Ontario, Canada
-$78K
Name Holding Trade Value Shares
Change 		Change in
Stake
HIM
1
HGC Investment Management
Ontario, Canada
– -$78K -1,214,583 Closed
PAMP
2
Polar Asset Management Partners
Ontario, Canada
– -$39.7K -620,800 Closed
AC
3
Aristeia Capital
Connecticut
– -$37.4K -601,133 Closed
RA
4
Ramius Advisors
New York
– -$36.4K -569,526 Closed
CCP
5
Corbin Capital Partners
New York
– -$29.7K -464,062 Closed
QGA
6
Q Global Advisors
Texas
– -$19K -300,000 Closed
ACM
7
Atalaya Capital Management
New York
– -$16.7K -278,437 Closed
LA
8
Linden Advisors
New York
– -$15.4K -245,467 Closed
RCM
9
Radcliffe Capital Management
Pennsylvania
– -$2.05M -202,950 Closed
SCM
10
Shaolin Capital Management
Florida
– -$13K -200,010 Closed
DKCM
11
Davidson Kempner Capital Management
New York
– -$9K -150,000 Closed
SC
12
Sculptor Capital
New York
– -$9.32K -150,000 Closed
TCM
13
Tenor Capital Management
New York
– -$8.96K -140,290 Closed
MI
14
MMCAP International
Cayman Islands
– -$8.95K -140,000 Closed
RCM
15
Rivernorth Capital Management
Florida
– -$6.65K -110,837 Closed
AC
16
Antara Capital
New York
– -$7K -110,000 Closed
ACA
17
Arena Capital Advisors
California
– -$6.39K -100,000 Closed
CH
18
CVI Holdings
Delaware
– -$6.39K -100,000 Closed
PC
19
Periscope Capital
Ontario, Canada
– -$6.39K -100,000 Closed
HF
20
HRT Financial
New York
– -$4K -66,828 Closed
Walleye Capital
21
Walleye Capital
New York
– -$4.14K -64,791 Closed
KPF
22
K2 Principal Fund
Ontario, Canada
– -$3.91K -61,201 Closed
BFM
23
Boothbay Fund Management
New York
– -$611K -60,493 Closed
WA
24
Whitebox Advisors
Minnesota
– -$3.67K -57,500 Closed
Jane Street
25
Jane Street
New York
– -$3.36K -52,649 Closed
1
2

BIOTW Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q1 2023, worth a combined $0 — down 100% from $3.83M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of BIOTW and 0 opened new positions — a net loss of 47 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Radcliffe Capital Management, exiting entirely with an estimated $2.05M sold.

  • 0 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q1 2023, down from 48 in Q4 2022.
  • Funds reported $0 of Biotech Acquisition Company Warrant stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Biotech Acquisition Company Warrant positions in Q1 2023 and 47 closed out, a net change of -47 holders.
  • The largest Biotech Acquisition Company Warrant seller in Q1 2023 was Radcliffe Capital Management, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2023.